SPAC513.04 Antibody

What is SPAC513.04 and why is it significant in fission yeast research?

SPAC513.04 is a gene in Schizosaccharomyces pombe that encodes an uncharacterized protein C513.04. It is classified as a "sequence orphan," meaning it lacks significant sequence homology to characterized proteins in other organisms . This makes it particularly interesting for researchers studying unique aspects of fission yeast biology and evolution. The significance lies in understanding novel protein functions that may be specific to S. pombe and potentially revealing new cellular mechanisms. Researchers typically approach this by utilizing specific antibodies to detect, localize, and characterize the protein's expression patterns under various conditions.

What forms of SPAC513.04 antibodies are currently available for research?

Currently, researchers have access to three primary SPAC513.04-related products. First, there is a rabbit polyclonal antibody specifically targeting SPAC513.04 in Schizosaccharomyces pombe (strain 972/24843) . This antibody is purified using antigen-affinity methods and is of the IgG isotype. Additionally, two recombinant protein forms are available: a complete recombinant SPAC513.04 protein produced in a cell-free expression system, and a partial recombinant SPAC513.04 protein that can be expressed in multiple host systems including E. coli, yeast, baculovirus, or mammalian cells . Both recombinant proteins achieve a purity of at least 85% as determined by SDS-PAGE analysis.

What applications have been validated for the rabbit anti-SPAC513.04 polyclonal antibody?

The rabbit anti-SPAC513.04 polyclonal antibody has been validated for two primary applications: Enzyme-Linked Immunosorbent Assay (ELISA) and Western Blot analysis . For ELISA applications, the antibody can be used to detect and quantify SPAC513.04 protein in complex biological samples. In Western Blot applications, the antibody effectively identifies the SPAC513.04 protein after separation by gel electrophoresis. The specificity of the antibody for these applications is ensured through antigen-affinity purification methods. Researchers should optimize antibody dilutions for their specific experimental conditions, typically starting with the manufacturer's recommended dilution ranges and adjusting based on signal-to-noise ratios observed in preliminary experiments.

What is the significance of SPAC513.04 being classified as a "sequence orphan"?

SPAC513.04's classification as a "sequence orphan" indicates that it lacks significant sequence homology to characterized proteins in other organisms . This classification has several important research implications. First, it suggests that the protein may perform functions unique to S. pombe or closely related fungi. Second, it presents challenges for functional prediction based on sequence analysis alone, necessitating experimental approaches using tools like antibodies. Third, characterizing such orphan proteins can potentially reveal novel protein domains, structures, or functions that expand our understanding of protein biology. Research approaches typically involve combining antibody-based detection with genetic manipulation (knockout, overexpression) and localization studies to gradually unveil the protein's biological role.

How can researchers optimize SPAC513.04 antibody specificity for detecting low-abundance protein expression?

Optimizing antibody specificity for low-abundance proteins like SPAC513.04 requires a multi-faceted approach. First, implement a pre-adsorption step by incubating the antibody with a lysate from SPAC513.04 knockout strains to remove cross-reactive antibodies. Second, optimize blocking conditions using 5% BSA instead of milk, which can reduce background without compromising specific signal. Third, increase the antibody incubation time to 16-18 hours at 4°C to maximize binding to low-abundance targets. Fourth, employ signal amplification systems such as biotin-streptavidin or tyramide signal amplification for detection.

The following table outlines recommended optimization parameters:

Validate specificity through parallel experiments using knockout controls and peptide competition assays to ensure signals represent authentic SPAC513.04 detection.

What approaches can be used to distinguish between specific and non-specific binding when working with SPAC513.04 antibody?

Distinguishing specific from non-specific binding is crucial when working with antibodies against uncharacterized proteins like SPAC513.04. First, employ genetic controls by comparing antibody reactivity in wild-type versus SPAC513.04 deletion strains; specific signals should disappear in the deletion strain. Second, conduct peptide competition assays where pre-incubating the antibody with purified recombinant SPAC513.04 protein should abolish specific signals. Third, use secondary antibody-only controls to identify background issues arising from the detection system.

For Western blot applications, analyze band patterns carefully. The SPAC513.04 protein should appear at its predicted molecular weight (calculable from its amino acid sequence), while non-specific bands will appear regardless of SPAC513.04 expression. For immunofluorescence, perform parallel staining with pre-immune serum to identify inherent background. Additionally, cross-validate findings using multiple antibody-independent methods, such as epitope tagging of SPAC513.04 followed by detection with tag-specific antibodies, which can confirm the authenticity of observed patterns.

How can the SPAC513.04 antibody be utilized to investigate protein-protein interactions in fission yeast?

Investigating protein-protein interactions involving SPAC513.04 requires methodical approaches utilizing the available antibody. Co-immunoprecipitation (Co-IP) represents the primary method, where the anti-SPAC513.04 antibody is immobilized on protein A/G beads to capture SPAC513.04 along with its interacting partners. For optimal results, cell lysis conditions should preserve native protein complexes using gentle detergents like 0.5% NP-40 or 1% Digitonin.

Proximity ligation assay (PLA) offers an alternative for detecting in situ interactions, combining the SPAC513.04 antibody with antibodies against suspected interaction partners. This technique can visualize interactions occurring within 40nm distance in intact cells. For validation, reciprocal Co-IPs should be performed where antibodies against putative interaction partners are used to capture complexes, followed by SPAC513.04 detection via Western blot.

If working with tagged versions of SPAC513.04, BioID or APEX2 proximity labeling can map the protein's interaction network by fusing these enzymes to SPAC513.04, allowing biotinylation of proximal proteins. The anti-SPAC513.04 antibody then verifies expression of the fusion protein, while streptavidin captures biotinylated partners for mass spectrometry identification.

What experimental design considerations are crucial when using SPAC513.04 antibody for quantitative analysis of protein expression across different cellular conditions?

When designing experiments for quantitative analysis of SPAC513.04 expression, several critical factors must be addressed. First, establish a calibration curve using purified recombinant SPAC513.04 protein at known concentrations to define the linear detection range of the antibody. Second, implement appropriate normalization controls by measuring multiple housekeeping proteins (such as Cdc2, Actin, and GAPDH) to account for loading variations.

Third, control for technical variability by using biological triplicates and technical duplicates at minimum. For Western blot quantification, use fluorescent secondary antibodies rather than chemiluminescence for more accurate quantitation across a broader dynamic range. For ELISA-based quantification, use a sandwich ELISA approach with a capture antibody against SPAC513.04 and a different detection antibody targeting another epitope.

The experimental design should incorporate appropriate statistical analysis, including ANOVA testing when comparing multiple conditions, followed by post-hoc tests. When measuring changes in SPAC513.04 expression across different cellular conditions, ensure all samples are processed identically and analyzed in parallel to minimize batch effects. Finally, validate antibody-based quantification with orthogonal methods such as RT-qPCR of SPAC513.04 mRNA or MS-based proteomics to corroborate protein level changes.

What are the optimal conditions for using the rabbit anti-SPAC513.04 polyclonal antibody in Western blot applications?

Optimal Western blot conditions for the rabbit anti-SPAC513.04 polyclonal antibody involve several critical parameters. Sample preparation should include protease inhibitors and cell lysis in RIPA buffer (150mM NaCl, 1% NP-40, 0.5% sodium deoxycholate, 0.1% SDS, 50mM Tris pH 8.0) with freshly added protease inhibitors. Load 30-50μg of total protein per lane on a 10-12% SDS-PAGE gel, depending on the predicted molecular weight of SPAC513.04.

After transfer to PVDF membrane (nitrocellulose is an acceptable alternative), block with 5% BSA in TBST for 1 hour at room temperature. Dilute the primary antibody 1:1000 in blocking solution and incubate overnight at 4°C with gentle rocking. Wash the membrane 4 times with TBST (5 minutes each) before applying HRP-conjugated anti-rabbit secondary antibody at 1:5000 dilution for 1 hour at room temperature.

For detection, both chemiluminescence and fluorescence-based systems are suitable, though fluorescence offers advantages for quantification. Include a molecular weight marker and a positive control (if available) on each blot. If high background is observed, increase the number and duration of wash steps and consider diluting the primary antibody further to 1:2000-1:5000.

How should SPAC513.04 antibody be validated for immunofluorescence studies in fission yeast?

Validating the SPAC513.04 antibody for immunofluorescence requires systematic controls and optimization. Begin with fixation method testing, comparing paraformaldehyde (3-4%, 15 minutes), methanol (-20°C, 6 minutes), and combination methods to determine which best preserves epitope recognition. For cell wall digestion, optimize using either zymolyase (1mg/mL, 30 minutes at 37°C) or lysing enzymes from Trichoderma harzianum (5mg/mL, 10-15 minutes).

Essential controls include:

• SPAC513.04 deletion strain - should show no specific signal

• Peptide competition - pre-incubating antibody with recombinant SPAC513.04 should abolish specific staining

• Secondary-only control - to assess background from secondary antibody

• Pre-immune serum control - to determine non-specific binding from the host animal

Test antibody concentrations ranging from 1:100 to 1:1000, and optimize permeabilization conditions using Triton X-100 (0.1-0.5%) or saponin (0.1-0.3%). To confirm specificity, cross-validate with GFP-tagged SPAC513.04 by performing co-localization analysis. If possible, use super-resolution microscopy techniques such as structured illumination microscopy (SIM) or stochastic optical reconstruction microscopy (STORM) to precisely define subcellular localization patterns.

What cell lysis and extraction methods are recommended for maximizing SPAC513.04 protein recovery when using this antibody?

The recovery of SPAC513.04 protein requires optimized cell lysis and extraction protocols tailored to its biochemical properties. As an uncharacterized protein, testing multiple extraction methods is advisable. Start with mechanical disruption of S. pombe cells using glass beads in a bead beater (6 cycles of 30 seconds on/30 seconds off) in cold lysis buffer. For soluble proteins, use a buffer containing 50mM Tris-HCl pH 7.5, 150mM NaCl, 1mM EDTA, 1mM DTT, and protease inhibitor cocktail.

For membrane-associated proteins, include detergents with increasing strength:

• Mild extraction: 0.5% NP-40 or 1% Triton X-100

• Moderate extraction: 1% CHAPS or 0.5% DDM

• Strong extraction: 0.1% SDS or 1% sodium deoxycholate

To recover nuclear proteins, add an additional extraction step with high salt (300-500mM NaCl) after initial lysis. For proteins in insoluble compartments, consider sequential extraction procedures, collecting and analyzing each fraction separately. After extraction, clarify lysates by centrifugation at 13,000×g for 15 minutes at 4°C.

The effectiveness of extraction should be validated by comparing protein recovery across different methods using Western blotting with the anti-SPAC513.04 antibody. Additionally, assess extraction efficiency by analyzing both pellet and supernatant fractions to confirm complete solubilization of the target protein.

What approaches are recommended for epitope mapping of the SPAC513.04 antibody to understand its binding specificity?

Epitope mapping of the SPAC513.04 antibody requires a systematic approach to identify its specific binding region. Begin with bioinformatic prediction tools such as BepiPred or DiscoTope to identify potential linear and conformational epitopes based on the SPAC513.04 protein sequence. Then design a series of overlapping peptides (15-20 amino acids with 5-10 amino acid overlaps) spanning the entire SPAC513.04 sequence.

Implement experimental approaches including:

• Peptide array analysis: Synthesize the overlapping peptides on a membrane and probe with the antibody to identify reactive fragments.

• Truncation analysis: Create a series of N-terminal and C-terminal truncations of SPAC513.04, express them recombinantly, and test antibody binding.

• Alanine scanning mutagenesis: For refined mapping, create point mutations changing key residues to alanine within the identified region.

• Hydrogen-deuterium exchange mass spectrometry (HDX-MS): For conformational epitopes, compare hydrogen-deuterium exchange patterns in the presence and absence of the antibody.

For polyclonal antibodies, consider immunodepletion experiments where the antibody is incubated with specific peptides to remove subpopulations binding to particular epitopes. Finally, validate the identified epitope by creating a synthetic peptide containing the epitope sequence and confirming it blocks antibody binding in Western blot or immunoprecipitation experiments.

How can researchers resolve weak or absent signals when using SPAC513.04 antibody in Western blot applications?

Weak or absent signals when using SPAC513.04 antibody in Western blot applications can be addressed through systematic troubleshooting. First, consider protein abundance issues - SPAC513.04 might be naturally expressed at low levels, requiring increased protein loading (50-100μg) or enrichment through immunoprecipitation before analysis. Second, optimize protein extraction using multiple lysis buffers with varying detergent compositions, as the protein might be sequestered in difficult-to-extract cellular compartments.

Third, investigate transfer efficiency by staining the membrane with Ponceau S after transfer and the gel with Coomassie Blue post-transfer to confirm proper protein migration. Fourth, modify blocking conditions, testing BSA, milk, or commercial blocking reagents that might preserve epitope accessibility. Fifth, increase antibody concentration incrementally (from 1:1000 to 1:100) while monitoring background levels.

For detection, employ more sensitive systems like enhanced chemiluminescence (ECL) Plus or Super Signal West Femto for chemiluminescence, or switch to fluorescence-based detection with longer exposure times. Additionally, consider membrane type (PVDF may retain more protein than nitrocellulose) and optimize antigen retrieval methods if fixation might be masking epitopes. Finally, confirm antibody viability by testing with a positive control of recombinant SPAC513.04 protein.

What strategies can researchers employ when encountering cross-reactivity or high background with SPAC513.04 antibody?

When encountering cross-reactivity or high background with SPAC513.04 antibody, multiple strategies can be implemented. First, increase stringency in blocking and washing steps by extending blocking time to 2 hours, using higher concentrations of blocking agents (5-10% BSA), adding 0.1-0.3% Tween-20 to all solutions, and performing additional wash steps (5-6 washes of 10 minutes each).

Second, optimize antibody dilutions by performing a dilution series (1:500, 1:1000, 1:2000, 1:5000) to identify the optimal concentration that maximizes specific signal while minimizing background. Third, pre-adsorb the antibody by incubating it with a lysate from cells lacking SPAC513.04 or with a related species to remove antibodies that contribute to cross-reactivity.

Fourth, modify secondary antibody parameters by reducing its concentration or switching to a more specific secondary antibody formulation, such as F(ab')2 fragments instead of whole IgG. Fifth, for Western blots, cut the membrane to include only the region of interest based on the predicted molecular weight of SPAC513.04, minimizing exposure to regions with non-specific binding.

Sixth, for immunofluorescence, include an additional blocking step with normal serum from the species in which the secondary antibody was raised. Finally, confirm specificity using peptide competition assays, where pre-incubation of the antibody with purified SPAC513.04 protein should eliminate specific signals but leave non-specific signals unchanged.

How should researchers interpret unexpected subcellular localization patterns when using SPAC513.04 antibody for immunofluorescence?

Interpreting unexpected subcellular localization patterns requires careful validation and consideration of biological context. First, confirm antibody specificity using deletion mutants and peptide competition assays to ensure the observed pattern represents authentic SPAC513.04 localization. Second, perform co-localization studies with established markers for various organelles (nucleus, ER, Golgi, mitochondria, vacuoles) to precisely define the unexpected compartment.

Third, investigate potential post-translational modifications or protein processing events by comparing the observed pattern with bioinformatic predictions for signal sequences, transmembrane domains, or localization signals in the SPAC513.04 sequence. Fourth, examine whether localization changes under different physiological conditions or cell cycle stages using synchronized cultures or specific environmental stresses.

Fifth, validate the immunofluorescence findings using complementary approaches such as subcellular fractionation followed by Western blotting, or expression of fluorescently-tagged SPAC513.04 for live cell imaging. Sixth, if the protein appears in multiple compartments, consider whether this represents actual biological distribution or artifacts of sample preparation.

Finally, explore the literature for proteins with similar localization patterns to generate hypotheses about possible functions. Unexpected localization often provides valuable clues about protein function, particularly for uncharacterized proteins like SPAC513.04, potentially revealing novel biological roles or regulatory mechanisms.

What data analysis approaches are recommended for quantifying SPAC513.04 expression levels across different experimental conditions?

Quantifying SPAC513.04 expression requires robust data analysis approaches. For Western blot quantification, use densitometry software that can distinguish between specific signal and background, such as ImageJ with the gel analysis tool. Normalize SPAC513.04 signal to multiple loading controls (tubulin, actin, and GAPDH) to account for potential variation in individual housekeeping proteins across conditions.

For more precise quantification, implement multiplexed detection using fluorescent secondary antibodies with distinct emission spectra for simultaneous detection of SPAC513.04 and loading controls, minimizing technical variation. Apply statistical analysis using at least three biological replicates per condition, employing paired t-tests for two-condition comparisons or ANOVA for multiple conditions.

The following data presentation methods are recommended:

For immunofluorescence quantification, employ automated image analysis with appropriate background subtraction and cell segmentation. Plot data with error bars representing standard deviation or standard error, and always include statistical significance indicators. For complex datasets, consider principal component analysis or hierarchical clustering to identify patterns across multiple conditions.

What are the most critical considerations for designing experiments with SPAC513.04 antibody to ensure reproducible results?

Ensuring reproducible results with SPAC513.04 antibody requires attention to several critical factors. First, implement comprehensive validation using genetic controls (deletion strains), recombinant protein controls, and multiple detection methods to confirm antibody specificity before proceeding with detailed experiments. Second, document and standardize all experimental parameters, including antibody lot numbers, incubation times, temperatures, buffer compositions, and detection settings.

Third, incorporate appropriate positive and negative controls in every experiment: positive controls using recombinant SPAC513.04 protein and negative controls such as immunodepleted antibody or knockout strains. Fourth, address biological variability by using sufficient biological replicates (minimum n=3) and technical replicates, while carefully controlling growth conditions for S. pombe cultures to ensure consistent protein expression.

Fifth, implement quantitative analysis methods with appropriate statistical testing, ensuring data normalization and reporting of both raw and normalized data. Sixth, validate key findings using orthogonal methods - for example, confirm Western blot results with mass spectrometry or RT-qPCR, and immunofluorescence results with fractionation studies.